Not sure what your sense is vs what Generex has stated. Generex stated they had great feedback on the pre IND and the FDA had additional testing requests which were started/completed. Also they were required to go the normal IND route and get everything done before submission of the IND application vs doing a rolling review application. Takes longer this way initially but hopefully it comes back with fewer additional requests.
(4)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links